TECENTRIQ

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Spain, Turkey, UK.

Active ingredients

The drug TECENTRIQ contains one active pharmaceutical ingredient (API):

1	Atezolizumab UNII 52CMI0WC3Y - ATEZOLIZUMAB
	Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity.
	Read more about Atezolizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TECENTRIQ Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FF05	Atezolizumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11277M, 11284X, 11297N, 11309F, 11792P, 11801D, 11802E, 11807K, 11926Q, 11927R, 11928T, 11929W, 11930X, 11931Y, 11940K, 11957H, 12076N, 12078Q, 12097Q, 12098R, 12155R, 12159Y, 12163E, 12164F, 12167J, 12168K, 12171N, 12174R
BR	Câmara de Regulação do Mercado de Medicamentos	529218020027002, 529219110026507
CA	Health Products and Food Branch	02462990, 02492393
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	125-MBE-0318, 203-MBE-0621
EE	Ravimiamet	1753747, 1800885
ES	Centro de información online de medicamentos de la AEMPS	1171220001, 1171220001IP, 1171220002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	494639, 533425
FR	Base de données publique des médicaments	60345905, 64422886
GB	Medicines & Healthcare Products Regulatory Agency	348083, 376167, 392553, 392555
HK	Department of Health Drug Office	65567, 66341, 66613
IL	מִשְׂרַד הַבְּרִיאוּת	8103, 8720
IT	Agenzia del Farmaco	045590015, 045590027
JP	医薬品医療機器総合機構	4291441A1024, 4291441A2020
LT	Valstybinė vaistų kontrolės tarnyba	1084155, 1088428
NL	Z-Index G-Standaard, PRK	148482, 199230
NZ	Medicines and Medical Devices Safety Authority	18470, 20388
PL	Rejestru Produktów Leczniczych	100395410, 100423803
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64295001, W66772001
SG	Health Sciences Authority	15425P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699505763323, 8699505763460
US	FDA, National Drug Code	50242-917, 50242-918